布地奈德联合PTCy方案预防异基因干细胞移植后急性胃肠道GVHD
一项前瞻性观察研究纳入80例接受异基因造血干细胞移植患者,在PTCy、他克莫司和吗替麦考酚酯基础上加用口服布地奈德预防胃肠道急性GVHD,并与CIBMTR公开数据集中646例接受PTCy方案者对照。布地奈德组3个月2-4级和3-4级aGVHD累积发生率显著低于对照组,1年GRFS、PFS和OS显著更高;倾向评分校正后aGVHD和cGVHD风险显著降低,GRFS、PFS和OS改善。结论认为加用布地奈德安全有效,可促进所有异基因移植受者转向外周血移植物。
要点
- 布地奈德组3个月2-4级aGVHD累积发生率3.8%,对照组34.4%(p<0.001)。
- 倾向评分校正后2-4级aGVHD风险HR 0.29(p<0.001),3-4级HR 0.12(p=0.045)。
- 布地奈德组1年GRFS 70.5% vs 对照组31.5%(p<0.001)。
核心结论
- 在PTCy为基础的GVHD预防方案中加用布地奈德可安全有效地预防严重急性胃肠道GVHD,并显著改善GRFS。
- 作者认为这些结果可能促进所有异基因移植受者转向外周血移植物。
研究设计与样本
- 前瞻性观察研究,纳入80例接受异基因造血干细胞移植的患者,中位年龄53岁(范围19-74岁)。
- 干预为在PTCy、他克莫司和吗替麦考酚酯基础上加用口服布地奈德。
- 对照组为公开可用的CIBMTR数据集中646例接受PTCy为基础GVHD预防的患者(CIBMTR Study # GV17-02)。
主要发现
- 3个月2-4级aGVHD累积发生率布地奈德组3.8% vs 对照组34.4%(p<0.001)。
- 3个月3-4级aGVHD累积发生率布地奈德组1.3% vs 对照组9.8%(p=0.029)。
- 1年GRFS布地奈德组70.5% vs 对照组31.5%(p<0.001),PFS 73.4% vs 52.8%(p=0.003),OS 80.1% vs 64.2%(p=0.038)。
- 倾向评分校正分析显示布地奈德显著降低2-4级aGVHD风险(HR 0.29,p<0.001)、3-4级aGVHD风险(HR 0.12,p=0.045)和cGVHD风险(HR 0.22,p<0.001),并改善GRFS(HR 0.38,p<0.001)、PFS(HR 0.58,p=0.012)和OS(HR 0.72,p=0.044)。
- 限制于单倍体移植受者的倾向评分匹配分析得到相似结果。
临床怎么用
- 原文结论认为在PTCy为基础的GVHD预防方案中加用布地奈德安全有效,可预防严重急性胃肠道GVHD并显著改善GRFS。
- 作者认为这些结果可能促进所有异基因移植受者转向外周血移植物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Oral budesonide exerts local effects with negligible systemic glucocorticoid activity, due to rapid first-pass metabolism, therefore, could potentially be efficacious in preventing gastrointestinal (GI) acute GVHD (aGVHD). We explored the use of budesonide, added to posttransplant cyclophosphamide (PTCy), tacrolimus, and mycophenolate mofetil, for prevention of GI aGVHD after allogeneic hematopoietic stem cell transplantation (AHSCT) in a prospective observational study and treated 80 patients with a median age of 53 years (range 19-74). Results were compared with a publicly available CIBMTR dataset of 646 patients who received PTCy-based GVHD prophylaxis (CIBMTR Study # GV17-02) (control). Cumulative incidence (CI) of 3-month grade 2-4 and grade 3-4 aGVHD in the budesonide and control groups were 3.8% vs. 34.4% (p < 0.001) and 1.3% vs. 9.8% (p = 0.029), respectively. One-year GRFS (70.5% vs. 31.5%, p < 0.001), PFS (73.4% vs. 52.8%, p = 0.003), and OS (80.1% vs. 64.2%, p = 0.038) were significantly higher in the budesonide group compared with control group. Propensity score-adjusted analyses showed that the addition of budesonide significantly decreased risk of aGVHD grade 2-4 (HR 0.29, p < 0.001), grade 3-4 (HR 0.12, p = 0.045), and cGVHD (HR 0.22, p < 0.001), which resulted in better GRFS (HR 0.38, p < 0.001), PFS (HR 0.58, p = 0.012), and OS (HR 0.72, p = 0.044). Similar results were found when using propensity score-matched analysis restricted to recipients of haploidentical transplantation. In conclusion, addition of budesonide to PTCy-based GVHD prophylaxis is safe and effective in preventing severe acute GI GVHD with significantly improved GRFS. These results could facilitate transition to peripheral blood grafts for all allogeneic transplant recipients.
引用
- Kongtim P, Chumnumsiriwath P, Vittayawacharin P, et al. Budesonide, Added to PTCy-Based Regimen, for Prevention of Acute GI GVHD After Allogeneic Stem Cell Transplantation. Am J Hematol. 2025. PMID: 39777927. doi:10.1002/ajh.27581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。